Chapter 7 146 Category Included terms Duration of treatment Duration of treatment Morbidity Morbidity Veno-venous hemofiltration Veno-venous hemofiltration Left ventricular ejection fraction Left ventricular ejection fraction Detailed description of ten randomly selected expanded access publications 1. Locati LD, Piovesan A, Durante C, et al. Realworld efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 2019;118:35–40. 2. Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res 2019;154:13–20. 3. Bonovas S, Piovani D. Compassionate Use of Remdesivir in Covid-19. N. Engl. J. Med. 2020;382:e101. 4. Huemer F, Melchardt T, Jansko B, et al. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. Eur J Haematol 2019;102:437–41. 5. Flaherty L, Hamid O, Linette G, et al. A SingleArm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. Cancer J 2014;20:18–24. 6. Breuer S, Maimon O, Appelbaum L, et al. TL-118anti-angiogenic treatment in pancreatic cancer: a case report. Med Oncol 2013;30:585. 7. Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013;24:1703–9. 8. Towner W, Lalezari J, Sension MG, et al. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr 2010;53:614–8. 9. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionateuse study. Br J Haematol 2008;111:1122–9. 10. Takahashi T, Prensner JR, Robson CD, et al. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases. Pediatr Blood Cancer 2020;67:e28636.
RkJQdWJsaXNoZXIy MTk4NDMw